ACE2 News and Research

RSS

Chronic illnesses promote active SARS-CoV-2 infection via suppressed mucosal immunity

A recent paper published in the preprint server medRxiv in September 2020 discusses the “clinically relevant variation in the expression of COVID-19-related genes”, which is associated with the host and environmental factors, as well as host genetic factors.

6 Oct 2020

Cats and dogs are low risk for SARS-CoV-2 transmission to humans

Researchers from the College of Veterinary Medicine and Biomedical Sciences, Colorado State University studied the possible transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among domestic cats and dogs.

5 Oct 2020

Production of six monoclonal antibodies against SARS-CoV-2 spike protein

Youjia Guo et al. in a recent bioRxiv preprint paper demonstrate the robust performance of mouse anti-SARS-CoV-2 spike monoclonal antibodies in immunoassays, including western blotting, ELISA, immunofluorescence, and immunoprecipitation and also neutralizing activity in vitro against SARS-CoV-2 infection.

5 Oct 2020

Development of a coarse-grained model of SARS-CoV-2 virion

A team of scientists of the University of Chicago and the University of California San Diego has developed a coarse-grained (CG) model of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virion. The model can be used as a valuable resource to perform multiscale simulations of the SARS-CoV-2 virion. The study is currently available on the bioRxiv* preprint server.

5 Oct 2020

Eli Lilly's LY-CoV555 antibody shows potential as COVID-19 treatment

Researchers in the United States and Canada have discovered a monoclonal antibody that potently neutralizes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent responsible for the current coronavirus disease 2019 (COVID-19) pandemic.

5 Oct 2020

New findings could improve investigation of T cell response to COVID-19

Researchers in the United States have made an important discovery about the processing and presentation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral peptides that provides a better understanding of the immune response to coronavirus disease 2019 (COVID-19) and may help facilitate the design of improved vaccines.

5 Oct 2020

Study confirms SARS-CoV-2 spike glycoprotein promotes a hyper-inflammatory immune response

A group of researchers from Australia and China recently demonstrated how SARS-CoV-2 spike glycoprotein subunit 1 can induce a pro-inflammatory signaling pathway (leading to cytokines deployment and epithelial damage in human bronchial epithelial cells), but also highlighted the potential of peptide-based antivirals in tackling this novel coronavirus.

5 Oct 2020

Macrophage subgroups may play pivotal role in COVID-19 lethality

Many researchers are attempting to identify risk factors for severe or critical COVID-19. A recent paper in the journal Medical Hypotheses in September 2020 suggests that macrophage class activation is one of the factors that determine the clinical phenotype of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

5 Oct 2020

Advanced model reveals dynamic motions of SARS-COV-2 spike-shielding glycans

A recent paper published on the preprint server bioRxiv in September 2020 discusses the dynamic interactions of the spike protein glycan shield, which may be of great value in developing therapeutic compounds to fight severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 Oct 2020

Sebum changes in COVID-19 patients, for future testing and prognosis

Now, a new study published on the preprint server medRxiv in September 2020 shows that sebum lipids change in COVID-19. This could help develop a cheap and straightforward method of non-invasive diagnosis.

5 Oct 2020

More evidence Pangolin not intermediary in transmission of SARS-CoV-2 to humans

The team proposed a different model named the ‘circulation model’ to illustrate how SARS-CoV-2-related coronaviruses could have circulated in different species, including humans, before COVID-19 emerged.

4 Oct 2020

Lung tissue in fatal COVID-19 shows broad cell tropism and extensive damage

In a recent preprint paper published on the medRxiv server, researchers demonstrated their investigation of fatal COVID-19 patients to assess infection in various cell types and the extent of damage it caused to the lung tissues.

30 Sep 2020

Maternal immune cells could bring SARS-CoV-2 to the placenta

Researchers from Canada and Brazil collaborated to explore the possibility of perinatal transmission of the virus from pregnant mothers to their babies and the risk of preterm birth.

30 Sep 2020

Discovery of high affinity binders for SARS-CoV-2 spike protein

An exciting, 'tour-de-force' paper by researchers from the Massachusetts Institute of Technology describes de novo discovery of high-affinity peptide binders for SARS-CoV-2 spike glycoprotein, which opens the door for the development of rapid viral identification or conjugates for virus-directed delivery of therapeutics.

30 Sep 2020

SARS-CoV-2 D614G variant enhances infectivity, replication and transmission

Researchers in the United States and Japan have conducted a study showing a common mutation in the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - the agent that causes coronavirus disease 2019 (COVD-19) - enhances the infectivity, replication, and early transmission of the virus.

30 Sep 2020

Newly developed fusion protein could improve COVID-19 research

Researchers at the Paul Scherrer Institute in Switzerland have developed a high-quality recombinant virus protein that could be applied in the development of vaccines against the 2019 novel coronavirus (2019-nCoV) and in the detection of novel viruses or antibodies.

30 Sep 2020

A TLR2 agonist reduces SARS-CoV-2 in upper respiratory tract of ferret model

In a recent bioRxiv* preprint paper, Professor Miles W. Carroll et al. study an agonist for reducing the SARS-CoV-2's viral load. They show that prophylactic intra-nasal administration of TLR2/6 (toll-like receptor) agonist, INNA-051, reduces viral RNA in the nose and throat, in a ferret model.

30 Sep 2020

New graphical tool to identify potent neutralizing antibodies against SARS-CoV-2

A new study by researchers at the Indian Institute of Science and the University of Queensland and published on the preprint server medRxiv in September 2020 discusses using a novel tool to identify the most effective among currently known anti-SARS-CoV-2 NAbs.

29 Sep 2020

SARS-CoV-2 infects human embryonic epithelial and lung cells

As COVID-19 continues to spread the world over, investigators are still trying to understand how it ravages the human body. A recent study published on the preprint server bioRxiv in September 2020 shows that the virus is capable of infecting human embryonic cells that are destined to form the epithelial surfaces of the body, both internal and external, as well as lung cells.

29 Sep 2020

Discovery of specific kinase as a novel drug target against SARS-CoV-2 and other coronaviruses

By using a modern genome-wide knockout approach to single out coronavirus host factors in human cells, researchers from Rega Institute in Belgium discovered a potential new target that might be exploited for developing drugs against the ongoing coronavirus disease (COVID-19) pandemic, but also future outbreaks of highly pathogenic coronaviruses

29 Sep 2020